Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis

BACKGROUND: We have previously conducted the Sirolimus and Autophagy Inhibition in LAM (SAIL) trial, a phase 1 dose-escalation study of the combination of sirolimus and hydroxychloroquine in patients with lymphangioleiomyomatosis (LAM). The goal of the present study was to analyze sera from the SAIL...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Chest
Autores principales: Lamattina, Anthony M., Taveira-Dasilva, Angelo, Goldberg, Hilary J., Bagwe, Shefali, Cui, Ye, Rosas, Ivan O., Moss, Joel, Henske, Elizabeth P., El-Chemaly, Souheil
Formato: Artigo
Lenguaje:Inglês
Publicado: American College of Chest Physicians 2018
Materias:
Diffuse Lung Disease
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6224706/
https://ncbi.nlm.nih.gov/pubmed/30144422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chest.2018.08.1029
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares